SCHEMBL9976008

SCHEMBL9976008

COc1cc(CCc2cc(=O)c3ccccc3o2)cc(OC)c1OC

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 3/20 0.64
▸ MEN1 O00255 4/20 0.48
▸ KMT2A Q03164 4/20 0.48
▸ CYP3A4 P08684 3/20 0.48
▸ MAPT P10636 3/20 0.48
▸ HPGD P15428 3/20 0.48
▸ MAPK1 P28482 3/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ ALDH1A1 P00352 2/20 0.48
▸ GLA P06280 1/20 0.48
▸ ABCB1 P08183 1/20 0.48
▸ THRB P10828 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ LCK P06239 1/20 0.47
▸ CYP11B1 P15538 1/20 0.47
▸ CYP11B2 P19099 1/20 0.47
▸ HTT P42858 1/20 0.46
▸ CYP1A1 P04798 1/20 0.46
▸ CYP1B1 Q16678 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30739469 0.84 CSNK2A2 (0.60) PPARGMEN1KMT2ACYP3A4MAPT
SCHEMBL29129665 0.84 CSNK2A2 (0.60) PPARGMEN1KMT2ACYP3A4MAPT
SCHEMBL8590731 0.82 PPARG (0.59) PPARGMEN1KMT2ACYP3A4MAPT
SCHEMBL30800380 0.82 PPARG (0.59) PPARGMEN1KMT2ACYP3A4MAPT
SCHEMBL8590733 0.82 PPARG (0.74) PPARGCYP3A4MAPTHPGDSMN1; SMN2
SCHEMBL30800382 0.81 PPARG (0.60) PPARGMEN1KMT2ACYP3A4MAPT
SCHEMBL29128893 0.81 PPARG (0.60) PPARGMEN1KMT2ACYP3A4MAPT
SCHEMBL7299375 0.81 SIGMAR1 (0.69) MEN1KMT2ACYP3A4KDM4EALDH1A1
SCHEMBL28874634 0.81 CYP3A4 (0.47) PPARGMEN1KMT2ACYP3A4MAPT
SCHEMBL29128897 0.80 PPARG (0.71) PPARGKMT2ACYP3A4MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546397-B2 DNA methylation inhibitors THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2013-10-01 — — US disclosed
US-8546397-B2 DNA methylation inhibitors THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2013-10-01 — — US disclosed
US-20120157465-A1 DNA METHYLATION INHIBITORS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2012-06-21 — — US disclosed
US-20120157465-A1 DNA METHYLATION INHIBITORS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2012-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157465-A1 DNA METHYLATION INHIBITORS MECP2, DNMT1, DNMT3B PPARG 3515/4885MEN1 3018/4885KMT2A 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback